► Episode 2 Considering Treatment for HER2-Negative Breast Cancer
Specifically looking into the human epidermal growth factor receptor 2 (HER2)-negative breast cancer setting, Joyce A. O’Shaughnessy, M.D., considers what treatment options were historically available for patients.
► Episode 3 BRCA Mutations in HER2-Negative Breast Cancer
Joyce A. O’Shaughnessy, M.D., provides considerations for the prevalence of BRCAmutations in human epidermal growth factor receptor 2 (HER2)-negative breast cancer and elucidates the role of mutational analysis in this setting.
► Episode 4 BRCA+ Breast Cancer: The Advent of PARP Inhibitors
Joyce A. O’Shaughnessy, MD, provides insight on the available poly ADP ribose polymerase (PARP) inhibitors with regard to their safety profiles and the rationale behind their development for BRCA-positive breast cancer.
► Episode 5 Future Role of PARP Inhibition in BRCA+ Breast Cancer
Looking to future therapeutic approaches and combinations, Joyce A. O’Shaughnessy, MD, reflects on the potential role of poly ADP ribose polymerase (PARP) inhibition for BRCA-positive breast cancer management.